Patanit Watanaboonyakhet, MD
Medical Oncology · Minot, NDNPI 1629143169
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $168 of the $194 with a category attached, or 86.7%. 9 manufacturers reported payments, led by Gilead at 28.0% of the total.
Across 13 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54
- Agios Pharmaceuticals, Inc.$34
- Genentech USA, Inc.$22
- Pfizer$17
- GSK$16
- Acrotech Biopharma Inc.$14
- plus $37 from 3 others
Across 9 payments — averaging $1987.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$17K
- Novartis$617
What the payments were for
- Food & beverage$16887%
- Education$2613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 4 | $54 |
| Agios Pharmaceuticals, Inc. | 2 | $34 |
| Genentech USA, Inc. | 1 | $22 |
| Pfizer | 1 | $17 |
| GSK | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
Too few medical oncology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 16 | $33,485 |
| EliquisApixaban | 19 | $13,088 |
| Anastrozole | 197 | $3,176 |
| Potassium Chloride | 34 | $1,130 |
| Letrozole | 66 | $1,066 |
| Acyclovir | 31 | $799 |
| Fluconazole | 16 | $747 |
| Hydroxyurea | 11 | $444 |
| Gabapentin | 25 | $378 |
| Pantoprazole Sodium | 15 | $353 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $299 |
| Dexamethasone | 18 | $239 |
| Prednisone | 34 | $236 |
| Warfarin Sodium | 24 | $168 |
| Levothyroxine Sodium | 19 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $13,08819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Minot
- Chad PedersenWatford City$74K
- Todor DentchevGrand Forks$11K
- Mark GitauFargo$1K
- Bassim KobrossyFargo$439
- John TateFargo$87
- Preston SteenFargo$44
- Denise SnowFargo$37
- Janet MacheledtFargo$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.